Lixte Biotechnology Holdings, Inc.
NASDAQ Capital MarketTotal Valuation
Lixte Biotechnology Holdings, Inc. carries a market capitalization of 89.11M, placing it among publicly traded companies globally. Its enterprise value stands at 34.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 89.11M |
| Enterprise Value | 34.29M |
Share Statistics
Lixte Biotechnology Holdings, Inc. currently has 11.63M shares outstanding.
| Shares Outstanding | 11.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 4.50 |
| P/TBV Ratio | 4.50 |
| P/FCF Ratio | -4.67 |
| P/OCF Ratio | -4.67 |
Financial Position
Lixte Biotechnology Holdings, Inc. maintains a current ratio of 2.78, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.49, indicating elevated leverage, while an interest coverage ratio of -700.53 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.78 |
| Quick Ratio | 2.65 |
| Debt / Equity | 6.49 |
| Debt / EBITDA | -0.09 |
| Interest Coverage | -700.53 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -116.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Lixte Biotechnology Holdings, Inc.'s stock has gained approximately 48.04928% over the past 52 weeks. The 50-day moving average sits at 5.83, while the 200-day moving average is 4.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | 48.04928% |
| 50-Day Moving Average | 5.83 |
| 200-Day Moving Average | 4.31 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -6.39M, while operating income came in at -6.39M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -6.39M |
| Pretax Income | -7.29M |
| Net Income | -7.22M |
| EBITDA | -6.39M |
| EBIT | -6.39M |
| Earnings Per Share (EPS) | -1.11 |
Balance Sheet
Lixte Biotechnology Holdings, Inc. holds 3.25M in cash and equivalents against 595,418.00 in total debt, resulting in a net debt position of -3.25M. Total book value stands at 7.95M, with working capital of 2.18M providing operational flexibility.
| Cash & Cash Equivalents | 3.25M |
| Total Debt | 595,418.00 |
| Net Debt | -3.25M |
| Equity (Book Value) | 7.95M |
| Book Value Per Share | 0.68 |
| Working Capital | 2.18M |
Cash Flow
Lixte Biotechnology Holdings, Inc. produced -4.33M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.33M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.33M |
| FCF Per Share | -0.66 |
Dividends & Yields
The company's payout ratio of 1.17 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 1.17 |
| Shareholder Yield | -26.31 |
| FCF Yield | -21.41 |
Stock Splits
Lixte Biotechnology Holdings, Inc.'s most recent stock split took place on June 5, 2023 with a 10:1 split ratio.
| Last Split Date | 6/5/2023 |
| Split Ratio | 10:1 |
Scores
Lixte Biotechnology Holdings, Inc. posts an Altman Z-Score of 3.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.27 |